Dragonfly's TriNKET compounds are designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The platform has also attracted partnerships from other pharma groups ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME ...

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...

Dec. 5, 2024 — Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...

BioArctic AB (publ) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed ...

Researchers uncovered a population of cells that may provide protection from brain injury following cardiac arrest, leading them to examine a drug that can activate these cells to improve neurological ...

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with a survival rate of just 11%. A primary culprit ...